This health care company focuses on animal well-being, offering medicines, vaccines, diagnostics, and precision tools for both pets and farm animals, which supports steady revenue from diverse markets.
The firm draws about two-thirds of sales from companion animal products like those for dogs, cats, and horses, while livestock segments cover cattle, swine, poultry, fish, and sheep. Growth comes from innovations such as new pain treatments for osteoarthritis in dogs and cats, plus expansions into international markets and alternative sales channels like retail. Recent earnings showed 4% organic revenue rise to $2.4 billion, with adjusted net income up 9%, driven by livestock gains of 10% from vaccines and key accounts. Risks include declines in some pain franchises due to market perceptions, plus softer vet visits impacting demand. Operations benefit from new facilities and partnerships for antibiotics. These elements foster reliable cash flows, enabling an 11% three-year dividend growth rate.
The company balances innovation with risk management, which aligns with dividend growth goals. We added this stock to the Dividend Growth Stocks Portfolio because its consistent increases and growth durability fit our mandate for long-term capital appreciation through compounding dividends. This move strengthens the portfolio’s exposure to resilient health care sectors.
